Hydreight Technologies Secures $10‑Million Bought‑Deal Private Placement

On January 16, 2026, Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) announced the closing of a $10‑million bought‑deal private placement, a move that underscores the company’s growing confidence in its health‑care technology platform. The financing was executed through a firm‑order agreement with Canaccord Genuity Corp. as the principal firm‑order buyer, in conjunction with a syndicate of additional firm‑order participants.

Structure of the Offering

Under the terms of the arrangement, Hydreight issued 2,470,000 shares (referred to as “units” in the filing) at an emission price of CAD 4.05 per unit. Each unit comprises one ordinary share and a half‑swing‑right to purchase an additional ordinary share at CAD 5.27 within a 24‑month window. The firm‑order participants were also granted an option to purchase up to an additional 50 % of the units at the same emission price, potentially adding another CAD 5,001,750 to the proceeds if fully exercised.

The net proceeds from the sale of the units were earmarked for several strategic priorities:

  • Expanding production capacity for the company’s pharmaceutical product lines.
  • Accelerating the launch of new, high‑demand products across its three operating segments.
  • Enhancing the technological and platform infrastructure that supports its nationwide digital health solutions.
  • Strengthening working capital and funding general corporate purposes.

Strategic Implications

Hydreight’s CEO, Shane Madden, highlighted the importance of the round in enabling the company to build on the momentum demonstrated in the fourth quarter. “The financing will allow us to accelerate the expansion of our proven pharmaceutical range and to launch high‑demand products that generate tangible, scalable growth,” he said. “It also provides the necessary resources to broaden our technological solutions and platform, increase production capacity, and meet rising demand across our national platform.”

The infusion of capital is expected to support the firm’s dual focus on scaling its digital health offerings and bolstering its pharmaceutical manufacturing capabilities. By tying the proceeds to both platform development and product launch, Hydreight is positioning itself to capture a larger share of the Canadian and U.S. markets where demand for integrated health‑tech solutions is rising.

Market Context

As of January 14, 2026, Hydreight’s share price stood at CAD 4.53, within the 52‑week range of CAD 1.00 to CAD 5.59. The company’s market capitalization hovered around CAD 225.8 million, and its price‑earnings ratio—at 350.93—reflects the speculative nature of many TSX Venture Exchange listings. Despite these valuation metrics, the firm’s recent transaction demonstrates a tangible step toward operational growth rather than merely capital‑raising.

The private placement also illustrates the broader trend of Canadian capital‑pool companies leveraging firm‑order mechanisms to secure funding quickly, bypassing the traditional prospectus route. This approach can provide flexibility and speed, both of which are crucial in the fast‑evolving health‑care technology landscape.

Outlook

Hydreight Technologies’ new capital base is expected to accelerate its expansion plans and reinforce its competitive position within the health‑care technology sector. The company will likely continue to pursue strategic initiatives that enhance its platform, diversify its product portfolio, and strengthen its foothold in North America. The successful closing of this private placement marks a significant milestone in Hydreight’s journey toward becoming a leading provider of digital health solutions and pharmaceutical services.